Dicerna announces the expiration of the waiting period for the Hart-Scott-Rodino Act for the acquisition of Dicerna by Synod – QNT Press Release

[ad_1]

Dicerna Pharmaceutical Company (Nasdaq:DNA) Announced today that, in accordance with the revised Hart-Scott-Rodino Antitrust Improvement Act of 1976 (“HSR”), the waiting period related to Novo Nordisk’s cash tender offer for Dicerna has ended in the evening Eastern Time 11:59 Expires on February 24, 2021.

As previously announced on November 18, 2021, Novo Nordisk began to acquire all issued ordinary shares of Dicerna in cash for $38.25 per share in cash, without interest, and withholding tax. The expiration of the high-speed rail waiting period has met one of the necessary conditions for the completion of the tender offer. Other conditions remain to be met, including, at the expiration of the offer, one more than 50% of Dicerna’s total issued shares will be bid for a minimum share. Unless the offer is postponed, the offer and the right to withdraw will expire on December 27, 2021 at 5 pm Eastern time.

About Dicerna

Dicerna Pharmaceuticals (NASDAQ:DNA) Is a biopharmaceutical company focused on the discovery, development and commercialization of drugs designed to use ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. Use our proprietary GalXC And GalXC-Plus With RNAi technology, Dicerna is committed to developing RNAi-based therapies with the potential to treat rare and more common diseases. By silencing disease-causing genes, Dicerna’s GalXC platform may solve diseases that are difficult to treat in other ways. Dicerna initially focused on disease-causing genes in the liver, and has been constantly innovating, and is exploring new applications of its RNAi technology and GalXC-Plus, which will extend the functions and applications of our flagship liver-targeted GalXC technology to tissues and cell types Outside the liver, it is possible to treat diseases across multiple therapeutic areas. In addition to our own core discovery and clinical drug candidate pipeline, Dicerna has also established partnerships with some of the world’s leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. between Dicerna and our partners, we currently have more than 20 active discovery, preclinical or clinical projects, focusing on cardiometabolic, viral, chronic liver and complement-mediated diseases, and Neurodegenerative diseases and pain. At Dicerna, our mission is to intervene-to silence genes, fight disease, and restore health.For more information, please visit www.Dicerna.com.

Forward-looking statements

The full story can be found on Benzinga.com

[ad_2]

Source link

Recommended For You

About the Author: News Center